Initial results of ensuing clinical trials indicate beneficial effects in a subset of patients treated with ICB and PARPi, with results from the MEDIOLA trial suggesting increased antitumor activity in germline BRCA mutated ovarian cancers treated with the combination therapy of olaparib and durvalumab (PD-L1 inhibitor) (Domchek et al. 2020). This evidence concerns the gene CD274 and ovarian carcinoma.